Expertise in
17
conditions

Dr. Elizabeth C. Verna

Gastroenterology
CUIMC/Presbyterian Hospital And Vanderbilt Clinic
622 W 168th St Fl 14, 
New York, NY 
Offers Telehealth
Expertise in
17
conditions
CUIMC/Presbyterian Hospital And Vanderbilt Clinic
622 W 168th St Fl 14, 
New York, NY 

Overview

Elizabeth Verna is a Gastroenterologist practicing medicine in New York, New York.

Dr. Verna is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Hepatitis, Hepatitis C, Liver Failure, Liver Transplant, and Kidney Transplant.

She is actively involved in clinical research, co-authoring 244 peer reviewed articles and participating in 13 clinical trials.

Specialties

Gastroenterology

Licenses

Internal Medicine in NY

Hospital Affiliations

New York-Presbyterian Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

CUIMC/Presbyterian Hospital and Vanderbilt Clinic
622 W 168th St Fl 14, New York, NY 10032
Other Locations
ColumbiaDoctors - 1 Pondfield Road
1 Pondfield Rd W Ste 2, Bronxville, NY 10708

Additional Areas of Focus

Dr. Verna has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
Enrollment Status: Completed
Publish Date: March 12, 2026
Intervention Type: Drug
Study Drug: Epclusa
Study Phase: Phase 2
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: February 18, 2026
Advancing Liver Therapeutic Approaches (ALTA). The ALTA Consortium Study Group for the Management of Portal Hypertension - A 5-year Longitudinal Observational Study of Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) Placement
Advancing Liver Therapeutic Approaches (ALTA). The ALTA Consortium Study Group for the Management of Portal Hypertension - A 5-year Longitudinal Observational Study of Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) Placement
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Enrollment Status: Terminated
Publish Date: September 17, 2025
Intervention Type: Other
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
Per-Oral Cholangioscopy in Liver Transplantation Patients
Per-Oral Cholangioscopy in Liver Transplantation Patients
Enrollment Status: Completed
Publish Date: July 28, 2022
Intervention Type: Device
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Enrollment Status: Completed
Publish Date: December 06, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug
Study Phase: Phase 2
PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver
PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver
Enrollment Status: Completed
Publish Date: March 03, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials

244 Total Publications

Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice.
Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice.
Journal: Gut microbes
Published: July 09, 2026
Similar Doctors
Expertise in
36
conditions
Dr. Thomas D. Schiano
Gastroenterology
Expertise in
36
conditions
Dr. Thomas D. Schiano
Gastroenterology
Referral may be required

Recanati Miller Transplantation Institute

5 E 98th St Fl 12, 
New York, NY 
 (3.3 miles away)
212-257-0031
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Schiano is a Gastroenterologist practicing medicine in New York, New York. Dr. Schiano is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Autoimmune Hepatitis, Liver Transplant, and Kidney Transplant. Dr. Schiano is currently accepting new patients.

Expertise in
18
conditions
Dr. David A. Katzka
Gastroenterology
Expertise in
18
conditions
Dr. David A. Katzka
Gastroenterology
Referral may be required

ColumbiaDoctors - Midtown

51 W 51st St Ste 360, 
New York, NY 
 (5.6 miles away)
646-661-2756
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Katzka is a Gastroenterologist practicing medicine in New York, New York. Dr. Katzka is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Esophagitis, Eosinophilic Esophagitis, Barrett Esophagus, Endoscopy, and Gastrectomy.

Expertise in
38
conditions
Dr. Michel Kahaleh
Gastroenterology
Expertise in
38
conditions
Dr. Michel Kahaleh
Gastroenterology
Referral may be required
Before you request

HMH Advanced And Therapeutic Endoscopy

186 Rochelle Avenue, 
Rochelle Park, NJ 
 (8.6 miles away)
551-996-1817
Languages Spoken:
English, Arabic, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michel Kahaleh is a Gastroenterologist practicing medicine in Rochelle Park, New Jersey. Dr. Kahaleh is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Achalasia, Pancreatic Pseudocyst, Bile Duct Obstruction, Endoscopy, and Gastric Bypass. Dr. Kahaleh is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Kahaleh is currently accepting new patients.

Frequently Asked Questions about Dr. Elizabeth C. Verna

How do I make an appointment with Dr. Elizabeth C. Verna?

You can book an appointment with Dr. Elizabeth C. Verna by calling their office at 347-378-3488. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Elizabeth C. Verna a top-rated expert for Liver Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Elizabeth C. Verna is classified as an Elite expert for Liver Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Elizabeth C. Verna specialize in?

While Dr. Elizabeth C. Verna is a Gastroenterology, they have specific expertise in Liver Transplant, Hepatitis, and Hepatitis C. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Elizabeth C. Verna participate in research or clinical trials?

Yes. Dr. Elizabeth C. Verna has published 244 articles and abstracts on conditions like Liver Transplant. You can view a list of Dr. Elizabeth C. Verna's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Elizabeth C. Verna accept my insurance?

Dr. Elizabeth C. Verna accepts most major insurance plans, including Anthem BCBS and Change Healthcare. We recommend calling the office directly at 347-378-3488 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Verna's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile